Press Releases

Press Releases

Media Contact:
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
wolffe@wheelhouselsa.com

Date Title and Summary Additional Format
January 7, 2021 Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies
Expansion of agreement results in an additional payment of $22 million to Nurix SAN FRANCISCO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. ( Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the expansion of its global strategic
January 5, 2021 Nurix Therapeutics Announces Presentation at 39th Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.  (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will present a corporate overview at the 39th Annual